KRAS and lung adenocarcinoma: Independent groups have reported DDR1 as a potential therapeutic candidate in KRAS-driven tumors (66, 66, 120), and combinatorial targeting of DDR1 has also been shown to be efficacious in KRAS-mutant tumors, lung adenocarcinoma (67), and recently pancreatic adenocarcinoma (121).